{"id":30001,"date":"2016-06-01T09:06:51","date_gmt":"2016-06-01T09:06:51","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=30001"},"modified":"2016-06-07T15:37:42","modified_gmt":"2016-06-07T15:37:42","slug":"paediatric-labeling-expanded-and-additional-tablet-strengths-for-ftctdf","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/30001","title":{"rendered":"Paediatric labeling expanded, and additional tablet strengths for FTC\/TDF"},"content":{"rendered":"

Simon Collins, HIV i-Base<\/strong><\/p>\n

The combined formulation of emtricitabine\/tenofovir disoproxil fumerate (FTC\/TDF) tablet label was recently updated to expand the indication to include paediatric patients weighing at least 17 kilograms.<\/strong><\/p>\n

New strength tablets are available: 100\/150 mg, 133\/200 mg and 167\/250 mg.<\/p>\n

A summary of the changes is included below but please see prescribing information for full details.<\/p>\n

Recommended dose<\/h2>\n

The recommended oral dose for pediatric patients weighing greater than or equal to 17 kg and who are able to swallow a whole tablet, is one low strength FTC\/TDF tablet (167 mg\/250 mg, 133 mg\/200 mg, or 100 mg\/150 mg based on body weight) taken orally once daily with or without food.<\/p>\n

The recommended oral dosage of TRUVADA low strength tablets is presented in Table 1. Weight should be monitored periodically and the dose adjusted accordingly.<\/p>\n\n\n\n\n\n\n
Table 1. Dosing for paediatric patients weighing 17 kg to less than 35 kg using FTC\/TDF low strength tablets<\/caption>\n
Body weight (kg)<\/th>\nDosing of FTC (mg)\/TDF (mg)<\/th>\n<\/tr>\n
17 to less than 22<\/td>\none 100\/150 tablet once daily<\/td>\n<\/tr>\n
22 to less than 28<\/td>\none 133\/200 tablet once daily<\/td>\n<\/tr>\n
28 to less than 35<\/td>\none 167\/250 tablet once daily<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Dose forms and strengths<\/h2>\n

TRUVADA tablets are available in three new dose strengths:<\/p>\n